Table 1.
Patient, disease, and treatment characteristics
| Patient Characteristics | |
|---|---|
| Median Age (range) |
61 years (42-92) |
| Percent (n) |
|
| Sex | |
| Male | 31% (31) |
| Female | 69% (68) |
| ECOG Performance Status | |
| 0 | 55% (54) |
| 1 | 41% (41) |
| 2 | 3% (3) |
| 3 | 1% (1) |
| Smoking Status | |
| Never | 45% (45) |
| Prior | 31% (31) |
| Current | 23% (23) |
| Immunosuppression | |
| None | 79% (78) |
| HIV | 10% (10) |
| Prior transplant | 5% (5) |
| Other | 6% (6) |
| BMI | |
| <20 | 7% (7) |
| 20-25 | 39% (39) |
| 25-30 | 30% (30) |
| >30 | 23% (23) |
| Disease and Treatment Characteristics | |
|---|---|
| Median Elapsed Days (range) | 43 days (10-68) |
| Percent (n) |
|
| T-stage | |
| 1 | 15% (15) |
| 2 | 45% (45) |
| 3 | 28% (28) |
| 4 | 11% (11) |
| N-stage | |
| 0 | 56% (55) |
| 1 | 20% (20) |
| 2 | 12% (12) |
| 3 | 12% (12) |
| Grade | |
| 1 | 13% (13) |
| 2 | 49% (49) |
| 3 | 19% (19) |
| na | 18% (18) |
| Chemotherapy | |
| 2× 5FU/MMC | 92% (91) |
| 1× 5FU/MMC | 5% (5) |
| 5FU or Cape | 3% (3) |
| Radiation Dose | |
| 50.4 Gy | 44% (44) |
| 54 Gy | 53% (52) |
| <50.4 Gy | 3% (3) |
5FU, 5-fluorouracil; BMI, body mass index; Cape, capecitabine; ECOG, Eastern Cooperative Oncology Group; MMC, mitomycin-C; N, node; na, not available; T, tumor.